September COVID-19 Inventor Showcase: A Breath Test for COVID-19
The CCTS’s Optimizing Innovation, Commercialization and Entrepreneurship of Biomedical Research program, in partnership with the Corporate Engagement Office and Nationwide Children's Hospital's Office of Technology Commercialization, is highlighting, on a monthly basis, experts who are working together at an unprecedented pace to fight against COVID-19 on the front lines of innovation.
The Novel Coronavirus Disease, COVID-19, was declared a pandemic by the World Health Organization (WHO). Without innate immunity to the novel virus and with the lack of therapeutic means to treat it, the only way to contain the spread of this disease further is through early diagnosis. For many infected individuals the disease remains asymptomatic- yet the disease carriers can potentially transmit COVID-19 and infect more of the population.
This work proves that there is a viable pathway towards the early and rapid detection of infection COVID-19 caused by the novel beta coronavirus SARS-CoV-2. Join us for a demonstration of a disruptive approach to infectious disease diagnosis and to the detection of COVID-19 specifically. This approach involves sampling the breath of humans for specific gaseous biomarkers of the disease and identifying a breath-print -signature of active COVID-19 infection.
Invention team
Perena Gouma, Ph.D.
Endowed Orton Chair in Ceramic Engineering
Andrew Bowman, MS, DVM, Ph.D.
Veterinary Preventative Medicine
Matthew Exline, M.D.
Pulmonary Disease & Critical Care Medicine
Innovation resource team
Caroline Crisafulli
Ohio State ADVANCE
Michelle Bright
Clinical Trials Management Organization
Ryan M. Haley, MBOE
Ambulatory Services, Wexner Medical Center